Table 1.
Primary liver cancer age-standardised incidence and incidence-based mortality rates 1997–2017, by nation, sex, and subtype.
| Incidence |
Incidence-based mortality |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N cases | Crude rate per 100,000 | ASR per 100,000 | 95% CI | Time period | APC | 95% CI | N deaths | Crude rate per 100,000 | ASMR per 100,000 | 95% CI | Time period | APC | 95% CI | |
| Overall | ||||||||||||||
| 82,024 | 6.3 | 7.3 | (7.2–7.3) | AAPC 1997–2017 | 4.1∗ | (3.4–4.7) | 58,348 | 4.5 | 5.2 | (5.2-5.2) | AAPC 1999-2017 | 4.5∗ | (4.1–4.8) | |
| 1997–2003 | 3.6∗ | (2.0–5.1) | 1999-2013 | 5.1∗ | (4.8–5.3) | |||||||||
| 2003–2014 | 5.9∗ | (5.3–6.4) | 2013-2017 | 2.4∗ | (1.1–3.8) | |||||||||
| 2014–2017 | -1.3 | (-4.1–1.5) | ||||||||||||
| Sex | ||||||||||||||
| Men | 52,258 | 8.2 | 10.5 | (10.4–10.6) | AAPC 1997–2017 | 4.5∗ | (3.8–5.2) | 36,373 | 5.7 | 7.4 | (7.3-7.5) | AAPC 1999-2017 | 4.4∗ | (3.9–4.8) |
| 1997–2014 | 5.4∗ | (5.0–5.8) | 1999-2013 | 4.9∗ | (4.6–5.3) | |||||||||
| 2014–2017 | -0.6 | (-4.6–3.5) | 2013-2017 | 2.5∗ | (0.8–4.3) | |||||||||
| Women | 29,766 | 4.5 | 4.7 | (4.6–4.7) | AAPC 1997–2017 | 3.6∗ | (2.9–4.2) | 21,975 | 3.3 | 3.5 | (3.4-3.5) | AAPC 1999-2017 | 4.2∗ | (3.7–4.8) |
| 1997–2003 | 2.6∗ | (0.9–4.2) | 1999-2013 | 4.8∗ | (4.4–5.3) | |||||||||
| 2003–2013 | 5.7∗ | (5.0–6.4) | 2013-2017 | 2.2 | (0.0–4.4) | |||||||||
| 2013–2017 | -0.1 | (-2.1–1.9) | ||||||||||||
| Country | ||||||||||||||
| England | 67,177 | 6.2 | 7.1 | (7.1–7.2) | AAPC 1997–2017 | 4.5∗ | (3.8–5.2) | 47,840 | 4.4 | 5.1 | (5.1-5.1) | AAPC 1999-2017 | 4.5∗ | (4.1–4.9) |
| 1997–2014 | 5.4∗ | (5.0–5.8) | 1999-2012 | 5.3∗ | (4.9–5.7) | |||||||||
| 2014–2017 | -0.4 | (-4.4–3.6) | 2012-2017 | 2.6∗ | (1.4–3.7) | |||||||||
| Wales | 4,502 | 7.1 | 7.5 | (7.3–7.8) | AAPC 1997–2017 | 3.2∗ | (1.0–5.5) | 3,232 | 5.1 | 5.4 | (5.2-5.6) | AAPC 1999-2017 | 4.0∗ | (3.0–4.9) |
| 1997–2015 | 4.7∗ | (3.8–5.7) | ||||||||||||
| 2015–2017 | -9.2 | (-27.5–13.7) | ||||||||||||
| Scotland | 8,572 | 7.9 | 8.9 | (8.7–9.1) | AAPC 1997–2017 | 3.7∗ | (1.4–6.2) | 6,087 | 5.6 | 6.3 | (6.2-6.5) | AAPC 1999-2017 | 4.7∗ | (3.9–5.5) |
| 1997–2010 | 3.5∗ | (2.4–4.6) | ||||||||||||
| 2010–2013 | 12.4 | (-3.6–31) | ||||||||||||
| 2013–2017 | -1.5 | (-5.7–2.8) | ||||||||||||
| NI | 1,773 | 4.8 | 6.3 | (6.0–6.6) | AAPC 1997–2017 | 4.5∗ | (3.3–5.8) | 1,189 | 3.2 | 4.3 | (4-4.5) | AAPC 1999-2017 | 5.6∗ | (3.9–7.4) |
| Subtype | ||||||||||||||
| HCC | 41,454 | 3.2 | 3.7 | (3.6–3.7) | AAPC 1997–2017 | 5.9∗ | (5.1–6.7) | 27,970 | 2.2 | 2.5 | (2.5-2.5) | AAPC 1999-2017 | 5.8∗ | (5.4–6.1) |
| 1997–2015 | 6.8∗ | (6.4–7.2) | ||||||||||||
| 2015–2017 | -1.5 | (-8.7–6.3) | ||||||||||||
| ICCA | 30,402 | 2.4 | 2.7 | (2.7–2.8) | AAPC 1997–2017 | 3.4∗ | (2.8–4.1) | 24,813 | 1.9 | 2.2 | (2.2-2.3) | AAPC 1999-2017 | 3.8∗ | (3.3–4.3) |
| 1997–2009 | 4.4∗ | (3.6–5.3) | 1999-2009 | 5.0∗ | (4.3–5.8) | |||||||||
| 2009–2017 | 2.0∗ | (0.8–3.2) | 2009-2017 | 2.2∗ | (1.4–3.0) | |||||||||
| Other | 10,165 | 0.8 | 0.9 | (0.9–0.9) | AAPC 1997–2017 | 0.3 | (-1.9–2.6) | 5,563 | 0.4 | 0.5 | (0.5-0.5) | AAPC 1999-2017 | 0.1 | (-4.3–4.7) |
| 1997–2005 | -2.5 | (-5.8–0.9) | 1999-2001 | -16.3 | (-36.2–9.7) | |||||||||
| 2005–2013 | 9.7∗ | (5.9–13.7) | 2001-2011 | 3.3∗ | (0.8–5.9) | |||||||||
| 2013–2017 | -11.0∗ | (-17.3–4.2) | 2011-2014 | 13.8 | (-8.8–41.9) | |||||||||
| 2014-2017 | -10.9∗ | (-20.2–0.5) | ||||||||||||
AAPC from best-fitting model given. If model has >1 joinpoint, APC for each time-period is also given. ∗The APC or AAPC is significantly different from zero at the alpha = 0.05 level. AAPC, average annual percentage change; APC, annual percentage change; ASR, age-standardised incidence rate; ASMR, age-standardised mortality rate; HCC, hepatocellular carcinoma; ICCA, intrahepatic cholangiocarcinoma; NI, Northern Ireland.